Trilaciclib: Experimental Treatment for Small Cell Lung Cancer (SCLC)

Scientific rationale and therapeutic potential

Trilaciclib is a short-acting CDK4/6 inhibitor given as an intravenous infusion prior to chemotherapy. Trilaciclib is designed to:

Clinical results (see: Publications)

Trilaciclib has potential in small cell lung cancer (SCLC) based on:

G1's ongoing Phase 2 trials in SCLC

G1T28-02 Trial

G1T28-03 Trial

G1T28-05 Trial

 


Click here for printable version of our trilaciclib SCLC clinical trials fact sheet